Neuroprotective and anti-neuroinflammatory properties of ebselen derivatives and their potential to inhibit neurodegeneration Article (Faculty180)

cited authors

  • Landgraf, Alexan D; Alsegiani, Am S; Alaqel, Saleh; Thanna, Sandeep; Shah, Z A; Sucheck, Steven J


  • Ebselen (EBS) is an organo-selenium containing compound that has anti-inflammatory, anti-tumor and anti-bacterial properties. EBS is being explored as a possible treatment for reperfusion injury, stroke, is under clinical trials as a mimetic of lithium in treatment of bipolar disorder1, and noise-induced hearing loss as a result of these actives2-5. However, we wanted to characterize derivatives of EBS as neuroprotective, anti-neuroinflammatory and antioxidant compounds. Recently, we have reported on a new thermal and photoinduced copper-mediated cross-coupling between potassium selenocyanate (KSeCN) and N-substituted ortho-halobenzamides to form ebselen derivatives with increased synthetic efficiency6. Our synthesis allows for the varying of the remote benzene ring with various substituents or replacing that ring with heterocyclic rings such as pyridine, pyrrole, thiophene, etc. In this study, we synthesized seven new heterocyclic EBS derivatives to further diversify our EBS library. These 21 compounds were then evaluated for their neuroprotective properties with four compounds showing an equal or better neuroprotective profile then EBS. Compounds 5, 9, 23, and 27 showed 86% 84%, 72% and 80% cell viability, respectively, at a 10 µM concentration. These studies were performed using human neuroblastoma SH-SY5Y cells in an oxygen and glucose deprivation (OGD) model of ischemia. At the same concentration these compounds significantly inhibited lipopolysaccharide (LPS) induced nitric oxide (NO) and tumor necrosis factor alpha (TNF-α) release from HMC3 microglial cells. Compounds 9 and 27 showed significantly increased cell viability (84% and 80% respectively) for neuronal cells exposed to microglia activated medium. These compounds showed only mild GPx-like reductive activity with compound 2, 7, 12, and 14 (115%, 96%, 95%, and 82% respectively) showing a higher percent rate of oxidation of NADPH in a coupled reaction assay compared to ebselen. This research highlights several derivatives of ebselen that show improved activity as neuroprotective agents over the parent compound.


publication date

  • 2020

published in